Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms

Abstract

Background: Postoperative adjuvant chemotherapy is not indicated for T1N1M0/ T2N0M0/T3N0M0 gastric cancer. However, approximately 10% to 30% of these patients experience recurrence and metastasis.Methods: Among 658 patients with gastric cancer who received gastrectomy with curative intent, 130 T1N1M0/T2N0M0 and 73 T3N0M0 patients were enrolled.Overall survival (OS) and relapse-free survival (RFS) were analyzed based on TP53 codon 72 polymorphisms Arg/Arg, Arg/Pro, and Pro/Pro. The hazard ratio (HR) for each subgroup was compared by TP53 codon 72 polymorphisms.Results: Of the 189 patients for whom polymorphism analysis results were available, the 5-and 10-year OS was 84.9% and 65.1%, respectively. The 5-and 10-year RFS was 81.8% and 65.4%, respectively. When the study cohort was divided into two groups according to polymorphism status (ie, "Arg/Arg and Arg/Pro" vs Pro/Pro), both the OS (HR, 2.799; 95% confidence interval [CI], 1.071-7.315; P = .036) and RFS (HR, 2.639; 95% CI, 1.025-6.794; P = .044) of the Pro/Pro group were significantly lower than those for the Arg/Arg and Arg/Pro groups across the entire observation period. Conclusions:The TP53 codon 72 Pro/Pro polymorphism may isolate a relatively high-risk patient group in T1N1M0/T2N0M0/T3N0M0 gastric cancer. K E Y W O R D S gastric cancer, postoperative adjuvant chemotherapy, T1N1M0/T2N0M0/T3N0M0, TP53 codon 72 polymorphism Members of Northern Gastric Cancer Study Consortium:

Dynamic phospho-proteogenomic analysis of gastric cancer cells suggests host immunity provides survival benefit

“…Anti-PD-L1/PD-1 antibodies together with an S-1 adjuvant chemotherapy containing the 5FU prodrug tegafur 3 , has become a standard treatment for locally advanced GC in Asia 40 . Based on the observation that the two 5FU-resistant cell lines showed increased levels of PD-L1 compared to their parental cell lines, we examined whether PD-L1 could be a prognostic factor for GC patients who underwent gastrectomy followed by S-1 adjuvant chemotherapy using the Northern Japan Gastric Cancer Study patient cohort 41,42,43 . Unexpectedly, neither overall survival (OS) nor the relapse-free survival (RFS) rate differed between surgery and S-1 adjuvant chemotherapy in PD-L1 − patients ( Fig.…”

Improved survival byHelicobacter pylori-modulated immunity in gastric cancer patients with S-1 adjuvant chemotherapy

“…The improved survival seen for advanced GC patients who are HP + compared to those who are HPsuggests that systemic effects that are chronically induced by HP infection may play a significant role in GC treatment efficacy (13,37). Importantly, many countries have reported similar trends, suggesting that the HP infection could have more dominant effects than a variety of treatments that are delivered in different countries and regions (10,12,38).…”

“…The survival status of the related subject cohort has been reported (13,36,37). Briefly, outcomes were evaluated for 13.3 years (median 5.3 years) for the 491 patients.…”